Pancreatic cancer: who works on it

One card per institution. Pick a target or a country to narrow the list.

• All targets
• KRAS 66
• PD-1 39
• TP53 4
• mTOR 0
• PI3K 0
• STAT3 0
• PD-L1 20
• CLDN18 21
• EGFR 11
• RAS 17
• BRCA2 8
• AKT 0
• BRCA1 10
• ERK 0
• MAPK 1
• PARP 9
• STING 0
• HER2 13
• MYC 0
• YAP 0
• MEK 5
• PALB2 9
• CTLA-4 9
• VEGF 3
• AMPK 0
• ATM 3
• CD40 2
• CXCR4 0
• HIF-1 0
• JNK 0
• NRF2 0
• CDKN2A 3
• GLP-1 2
• NRAS 5
• PRMT5 6
• IL-6 0
• PPAR 0
• PTEN 0
• BCL-2 0
• FAK 1
• IL-15 1
• JAK 0
• TROP2 3
• BRAF 2
• MET 2
• B7-H3 2
• CDK4/6 0
• CTNNB1 0
• FGFR 1
• HSP90 0
• HDAC 0
• KEAP1 1
• CD47 0
• METTL3 0
• MUC1 3
• AXL 1
• CCR5 0
• HER3 1
• HMGB1 1
• NTRK 1

24 of 26+ institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• NIH NCI · F31

  Assessing autophagic dependencies in the context of RAS inhibition in pancreatic ductal adenocarcinoma

  Univ of North Carolina Chapel Hill· Chapel Hill, United States· US$37,011 awarded in fiscal year 2026· until Sept 2029

• FDA · R01

  Safety and Efficacy of a Multi-Tumor-Associated Antigen-Specific T Cell Therapy in Pancreatic Cancer Patients

  Marker Therapeutics, Inc.· Houston, United States· US$645,493 awarded in fiscal year 2026· until Aug 2030

• NIH NIAMS · R21

  Nuclear Receptors In Cancer Cachexia

  University of Texas Hlth Sci Ctr Houston· Houston, United States· US$200,604 awarded in fiscal year 2026· until Jul 2028

• NIH NCI · U01

  The role of circadian gene regulation in pancreatic cancer progression and immune evasion

  University of Rochester· Rochester, United States· US$626,555 awarded in fiscal year 2026· until Aug 2031

• NIH NIAMS · R56

  Mitochondrial permeability transition in cancer cachexia

  University of Florida· Gainesville, United States· US$307,000 awarded in fiscal year 2026· until Aug 2027

• European Commission (Horizon Europe) · HORIZON-ERC

  Immunity under Pressure: Mapping Compression Driven Tumor–Immune Rewiring to Potentiate Immunotherapy in Pancreatic Cancer (MechanoImmunoMap)

  University of Cyprus· Nicosia, Cyprus· EU contribution €1,500,000· until Jan 2032

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Glycoengineering for Immune Modulation in Precision Anti-Cancer Therapies (GlycoIMPACT)

  Universitat Wien· Wien, Austria· EU contribution €230,185· until Dec 2028· 2 countries

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-DN

  Next-Generation Radiopharmaceuticals for Glioblastoma and Pancreatic Cancer: A 3D Perspective (radio3D)

  Agencia Estatal Consejo Superior de Investigaciones Cientificas· Madrid, Spain· EU contribution €4,366,500· until Dec 2030· 9 countries

• European Commission (Horizon Europe) · HORIZON-ERC

  Evoking anti-tumor immunity in pancreatic cancer (Evoke-PDAC)

  Deutsches Krebsforschungszentrum Heidelberg· Heidelberg, Germany· EU contribution €2,497,125· until Dec 2031

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-SE

  EXPLORING THE MECHANISM OF METASTASIS/DEVELOPMENT OF NEW TESTS TO ENROLL CIRCULATING TUMOR CELLS (CTCs) INTO CLINICAL PRACTICE (CTC4CLINIC)

  Panepistimio Patron· Rio Patras, Greece· EU contribution €796,590· until Dec 2030· 7 countries

10 of 864 running projects, newest first. Listed amounts together: US$468.4m + €177.8m.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Trials whose registry record says individual participant data (IPD) will be shared.

• Testing the Combination of Anetumab Ravtansine With Either Nivolumab, Nivolumab and Ipilimumab, or Gemcitabine and Nivolumab in Advanced Pancreatic Cancer

  NCT03816358· National Cancer Institute (NCI)· Source

• Vilastobart+Retifanlimab in BRCA or PALB2 Deficient PC

  NCT07765836· Massachusetts General Hospital· Source

• Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) in Previously Treated Participants With Select Solid Tumors (MK-7902-005/E7080-G000-224/LEAP-005)

  NCT03797326· Merck Sharp & Dohme LLC· Source

• INCB106385 Alone or in Combination With Immunotherapy in Advanced Solid Tumors

  NCT04580485· Incyte Corporation· Source

• Neoantigen Vaccine Plus Anti-PD1 and Chemotherapy as an Adjuvant Therapy for Pancreatic Cancer

  NCT06344156· Sichuan University· Source

• Stereotactic Body Radiotherapy Combined With PD-1 Blockers for Locally Advanced or Locally Recurrent Pancreatic Cancer

  NCT06195254· Peking University Third Hospital· Source

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 50
• Organoids 47
• Mendelian Randomization Analysis 29
• CRISPR-Cas Systems 16
• Gene Expression Profiling 123
• Sequence Analysis, RNA 11
• Whole Genome Sequencing 3
• Exome Sequencing 10
• Proteomics 55
• Metabolomics 34
• Mass Spectrometry 10
• Flow Cytometry 32
• Immunohistochemistry 70
• Liquid Biopsy 30
• Circulating Tumor DNA 29
• Xenograft Model Antitumor Assays 302
• Positron-Emission Tomography 30
• Magnetic Resonance Imaging 117
• Machine Learning 58
• Deep Learning 55
• Cohort Studies 108
• Genome-Wide Association Study 24

See which targets of this disease your abstract mentions, and go to the people working on them.